Understanding the Risks of Compounded Drugs
Compounded drugs are not FDA-approved. This means the agency does not verify their safety, effectiveness or quality before they are marketed.
Compounded drugs can serve an important medical need for patients. However, if a compounded drug does not meet appropriate quality standards – such as if a drug is contaminated or contains too much active ingredient – it could cause serious injury or death. Additionally, the labels on compounded drugs may not include important information such as adequate directions to help ensure the drugs are used safely.
The agency seeks to strike a balance between preserving access to lawfully-marketed compounded drugs for patients who have a medical need for them while protecting patients from the risks associated with compounded drugs that are not produced in accordance with applicable federal law.
FDA continues to investigate many reports of serious adverse events associated with contaminated or otherwise poor-quality compounded drugs. The agency continues to identify insanitary conditions at drug compounding facilities during inspections. Insanitary conditions can cause drugs to become contaminated and lead to serious patient injury and death.
Risk-based oversight, providing information about compounding regulation, policy development and fostering collaboration with states and stakeholders are vital to achieving broader compliance with the provisions of federal law intended to help protect patients.
Email us: compounding@fda.hhs.gov
Sign up for compounding emails
Quick Links
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
View of list of bulk drug substances nominated for use in compounding that may present significant safety risks to patients
Mitigating Risks of Compounded Drugs Through Surveillance
Learn how FDA identifies risks and the actions taken to mitigate them
Compounding Risk Alerts
Compounding risk alerts help health care professionals, compounders and patients understand risks associated with certain compounded drugs
FDA to Compounders: Know Your Bulks and Excipient Suppliers
FDA urges compounders to know their bulk drug substances and excipients suppliers and to know if the supplier is testing the components to ensure appropriate quality to use in drugs
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Find information about FDA’s concerns with compounded GLP-1 drugs
Compounding Research
Find information about external partnerships for compounding research